FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220730004> ?p ?o ?g. }

• W4220730004 endingPage "706" @default.
• W4220730004 startingPage "706" @default.
• W4220730004 abstract "Induction chemotherapy added to concurrent chemoradiotherapy significantly improves survival for patients with locoregionally advanced nasopharyngeal carcinoma, but the optimal induction regimen remains unclear.To determine whether induction chemotherapy with paclitaxel, cisplatin, and capecitabine (TPC) improves survival vs cisplatin and fluorouracil (PF) prior to chemoradiotherapy for patients with stage IVA to IVB nasopharyngeal carcinoma.This randomized, open-label, phase 3 clinical trial recruited 238 patients at 4 hospitals in China from October 20, 2016, to August 29, 2019. Patients were 18 to 65 years of age with treatment-naive, nonkeratinizing stage IVA to IVB nasopharyngeal carcinoma and an Eastern Cooperative Oncology Group performance status of 0 to 1.Patients were randomly assigned (1:1) to receive induction chemotherapy with two 21-day cycles of TPC (intravenous paclitaxel [150 mg/m2, day 1], intravenous cisplatin [60 mg/m2, day 1], and oral capecitabine [1000 mg/m2 orally twice daily, days 1-14]) or PF (intravenous cisplatin [100 mg/m2, day 1] and fluorouracil [800 mg/m2 daily, days 1-5]), followed by chemoradiotherapy.The primary end point was failure-free survival in the intention-to-treat population. Secondary end points included distant metastasis-free survival, locoregional relapse-free survival, overall survival, tumor response, and safety.Overall, 238 eligible patients (187 men [78.6%]; median age, 45 years [range, 18-65 years]) were randomly assigned to receive TPC (n = 118) or PF (n = 120). The median follow-up duration was 48.4 months (IQR, 39.6-53.3 months). Failure-free survival at 3 years was 83.5% (95% CI, 77.0%-90.6%) in the TPC group and 68.9% (95% CI, 61.1%-77.8%) in the PF group (stratified hazard ratio [HR] for recurrence or death, 0.47; 95% CI, 0.28-0.79; P = .004). Induction with the TPC regimen resulted in a significant reduction in the risk of distant metastases (stratified HR, 0.49 [95% CI, 0.24-0.98]; P = .04) and locoregional recurrence (stratified HR, 0.40 [95% CI, 0.18-0.93]; P = .03) compared with the PF regimen. However, there was no effect on early overall survival (stratified HR, 0.45 [95% CI, 0.17-1.18]; P = .10). The incidences of grade 3 to 4 acute adverse events and late-onset toxicities were 57.6% (n = 68) and 13.6% (16 of 118), respectively, in the TPC group and 65.8% (n = 79) and 17.9% (21 of 117), respectively, in the PF group. One treatment-related death occurred in the PF group.This randomized clinical trial found that induction chemotherapy with 2 cycles of TPC for patients with stage IVA to IVB nasopharyngeal carcinoma improved failure-free survival compared with 2 cycles of PF, with no increase in the toxicity profile.ClinicalTrials.gov Identifier: NCT02940925." @default.
• W4220730004 created "2022-04-03" @default.
• W4220730004 creator A5000116678 @default.
• W4220730004 creator A5000813286 @default.
• W4220730004 creator A5002277933 @default.
• W4220730004 creator A5005782389 @default.
• W4220730004 creator A5006827480 @default.
• W4220730004 creator A5009521293 @default.
• W4220730004 creator A5011622378 @default.
• W4220730004 creator A5019839277 @default.
• W4220730004 creator A5023349881 @default.
• W4220730004 creator A5025156587 @default.
• W4220730004 creator A5026796732 @default.
• W4220730004 creator A5027407618 @default.
• W4220730004 creator A5031807880 @default.
• W4220730004 creator A5032614467 @default.
• W4220730004 creator A5037660489 @default.
• W4220730004 creator A5042573668 @default.
• W4220730004 creator A5042578262 @default.
• W4220730004 creator A5048052584 @default.
• W4220730004 creator A5051808133 @default.
• W4220730004 creator A5053275663 @default.
• W4220730004 creator A5055665508 @default.
• W4220730004 creator A5057532517 @default.
• W4220730004 creator A5059140670 @default.
• W4220730004 creator A5059928860 @default.
• W4220730004 creator A5061152137 @default.
• W4220730004 creator A5063089557 @default.
• W4220730004 creator A5063145199 @default.
• W4220730004 creator A5069882719 @default.
• W4220730004 creator A5070688328 @default.
• W4220730004 creator A5071191068 @default.
• W4220730004 creator A5078326314 @default.
• W4220730004 creator A5081900645 @default.
• W4220730004 creator A5084047711 @default.
• W4220730004 creator A5085762574 @default.
• W4220730004 creator A5087898022 @default.
• W4220730004 date "2022-05-01" @default.
• W4220730004 modified "2023-10-11" @default.
• W4220730004 title "Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma" @default.
• W4220730004 cites W1902822116 @default.
• W4220730004 cites W1974990780 @default.
• W4220730004 cites W1983970003 @default.
• W4220730004 cites W1984396523 @default.
• W4220730004 cites W1988166003 @default.
• W4220730004 cites W1990153402 @default.
• W4220730004 cites W2019328052 @default.
• W4220730004 cites W2019607817 @default.
• W4220730004 cites W2030180893 @default.
• W4220730004 cites W2031654287 @default.
• W4220730004 cites W2043367053 @default.
• W4220730004 cites W2043945205 @default.
• W4220730004 cites W2044736010 @default.
• W4220730004 cites W2064659229 @default.
• W4220730004 cites W2075214861 @default.
• W4220730004 cites W2075346894 @default.
• W4220730004 cites W2111140446 @default.
• W4220730004 cites W2125919881 @default.
• W4220730004 cites W2133134887 @default.
• W4220730004 cites W2137178561 @default.
• W4220730004 cites W2141592118 @default.
• W4220730004 cites W2160982012 @default.
• W4220730004 cites W2166243031 @default.
• W4220730004 cites W2174306046 @default.
• W4220730004 cites W2202977982 @default.
• W4220730004 cites W2346249331 @default.
• W4220730004 cites W2472921249 @default.
• W4220730004 cites W2479717569 @default.
• W4220730004 cites W2522328871 @default.
• W4220730004 cites W2526747727 @default.
• W4220730004 cites W2533168241 @default.
• W4220730004 cites W2559861554 @default.
• W4220730004 cites W2588073896 @default.
• W4220730004 cites W2775830207 @default.
• W4220730004 cites W2779452291 @default.
• W4220730004 cites W2883587006 @default.
• W4220730004 cites W2944446972 @default.
• W4220730004 cites W2947165726 @default.
• W4220730004 cites W3012929857 @default.
• W4220730004 cites W3022312939 @default.
• W4220730004 cites W3038128967 @default.
• W4220730004 cites W3115270218 @default.
• W4220730004 cites W3115988948 @default.
• W4220730004 cites W3118937854 @default.
• W4220730004 cites W3156377991 @default.
• W4220730004 cites W3165445830 @default.
• W4220730004 cites W3170343664 @default.
• W4220730004 cites W3177382619 @default.
• W4220730004 cites W4211017340 @default.
• W4220730004 cites W4238954401 @default.
• W4220730004 cites W4247675355 @default.
• W4220730004 cites W4253852052 @default.
• W4220730004 cites W4292528167 @default.
• W4220730004 doi "https://doi.org/10.1001/jamaoncol.2022.0122" @default.
• W4220730004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35323856" @default.
• W4220730004 hasPublicationYear "2022" @default.
• W4220730004 type Work @default.
• W4220730004 citedByCount "16" @default.

• next